Phaseline

Targets › HTR4

HTR4 (5-hydroxytryptamine receptor 4): drug programs, companies and trials

7 programs from 7 companies in 10 trials: 5 Phase 3, 2 Phase 2, 2 Phase 4, 1 Phase 1; Other, Gastroenterology, Infectious disease; next expected readout Dec 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors. (UniProt, Q13639)

Open in Phaseline: the race on HTR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sanliurfa Education and Research Hospitalmetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 4Intraoperative Nausea-retching-vomiting EpisodesJan 2027
Boston Children's HospitalPrucalopride
Serotonin 4 (5-HT4) receptor agonist
HTR4Phase 4Esophageal Motility DisordersMay 2027
Valenta Pharm JSC4-MUST (trimebutine 4-methylumbelliferyl sulfate)
Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis
TRPV1, HTR4Phase 3Chronic CholecystitisDec 2026
Affiliated Hospital of Qinghai UniversityMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 3NauseaDec 2027
Tanta UniversityItopride
5-HT4 receptor partial agonist and dopamine antagonist
HTR4Phase 3Spontaneous Bacterial PeritonitisDec 2028
Future University in EgyptPrucalopride
Serotonin 4 (5-HT4) receptor agonist
HTR4Phase 3Post-Op Complication–
Simon FisherMetoclopramide
Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist
DRD2, HTR3A, HTR4Phase 2Hypoglycemia UnawarenessJun 2027

Conditions

Chronic Cholecystitis (3) Post-Op Complication (2) Nausea (1) Intraoperative Nausea-retching-vomiting Episodes (1) Spontaneous Bacterial Peritonitis (1) Hypoglycemia Unawareness (1) Esophageal Motility Disorders (1)

Modalities

small molecule (7)

Companies

Future University in Egypt (1) Valenta Pharm JSC (1) Affiliated Hospital of Qinghai University (1) Sanliurfa Education and Research Hospital (1) Tanta University (1) Simon Fisher (1) Boston Children's Hospital (1)

Related targets

DRD2 (3) HTR3A (3) TRPV1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.